Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) unit, Fujian Shengdi Pharmaceutical, received approval from China's National Medical Products Administration to conduct clinical trials on HRS-1596 tablets, according to a Tuesday disclosure on the Shanghai bourse.
The drug will be tested as a weight management product and as a treatment for type 2 diabetes mellitus.
The pharmaceutical company's Hong Kong shares fell 3% and Shanghai shares slipped 1% during the morning trade.